Preeklampsia – Nga fiziopatologjia tek mjekimi

Autori

  • Enton Kaçulini
  • Alketa Koroshi
  • Alma Idrizi
  • Alma Shehu

DOI:

https://doi.org/10.55312/op.vi2.4521

Abstract

Preeklampsia është një çrregullim multisistemik karakteristik për shtatzëninë humane dhe ndërlikimi glomerular më i shpeshtë në shtatzëni. Ajo haset në 2% deri 8% të shtatzënive dhe është një kontribuuese e rëndësishme e vdekshmërisë amtare në të gjithë botën. Edhe pse fi ziopatologjia e preeklampsisë nuk njihet plotësisht, në të përfshihen mekanizma patogjenetikë të shumtë. Placenta luan një rol thelbësor në shfaqjen e këtij çrregullimi. Mekanizmat patogjenetikë të implikuar në preeklampsi, përfshijnë zhvillimin jonormal të placentës, stresin oksidativ dhe atë të rrjetit endoplazmatik, auto-antitrupat ndaj receptorit tip-1 të angiotenziongjenit, aktivizimin e trombinës dhe trombociteve, disfunksionin endotelial dhe prishjen e ekuilibrit ndërmjet faktorëve angiogjenik dhe antiangiogjenik, në dukje mekanizmi më i rëndësishëm.

Parole chiave:

preeklamps, fi ziopatologji, shtatzëni.

Downloads

I dati di download non sono ancora disponibili.

Riferimenti bibliografici

  1. National Kidney Foundation’s primer on kidney diseases/[edited by] Scott J. Gilbert, Daniel E. Weiner; associate editors, Debbie S. Gipson, Mark A. Perazella, Marcello Tonelli. -- Sixth edition (2014); p: 430.

  2. Thomas M. Coff man et al. Schrier’s Diseases of the Kidney, 9th ed. (2015), p:1697-1700.

  3. Jebbink J, Wolters A, Fernando F, et al. Molecular genetics of preeclampsia and HELLP syndrome: A review. Biochim Biophys Acta. 2012. Available at: .

  4. Pettit F, Brown MA. The management of preeclampsia: What we think we know. Eur J Obstet Gynecol Reprod Biol. 2012; 160:6-12.

  5. Bhattacharya S, Campbell DM, Smith NC. Preeclampsia in the second pregnancy: Does previous outcome matter? Eur J Obstet Gynecol Reprod Biol. 2009; 144:130-134.

  6. RJ. Johnson, J. Feehally, J. Floege. Comprehensive Clinical Nephrology 5th ed. 2014; p: 506-521.

  7. Conde-Agudelo A, Althabe F, Belizan JM, Kafury-Goeta AC. Cigarette smoking during pregnancy and risk of preeclampsia:

  8. A systemic review. Am J Obstet Gynecol. 1999; 181:1026-1035.

  9. Maarten W. Taal et al. Brenner and Rector’s The Kidney, 9th Edition. p:1795-1808.

  10. F. Gary Cunningham, MD, Kenneth J. Leveno, MD, Steven L. Bloom, MD, Catherine Y. Spong, MD, Jodi S. Dashe, MD, Barbara L. Hoff man, MD, Brian M. Casey, MD, Jeanne S. Sheffi eld, MD. Williams Obstetrics 24/E 24th Edition. 2014; p. 731, 732.

  11. http://www.rcdrg.sgul.ac.uk/research/trophoblasts

  12. Pijnenborg R, Anthony J, Davey DA, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol. 1991; 98:648-655.

  13. Brosens, I., Robertson, W. B. & Dixon, H.G. The physiological response of the vessels of the placental bed to normal pregnancy. J.

  14. Pathol. Bacteriol. 93, 569–579 (1967).

  15. Zhou, Y., Damsky, C. H. & Fisher, S. J. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J. Clin. Invest. 99, 2152–2164 (1997).

  16. Zhou Y., Damsky C. H., Fisher S. J. (1997). Preeclampsia is associated with failure of human cytotrophoblasts to mimic vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest. 99:2152–2164.

  17. Hertig, A. T. Vascular pathology in hypertensive albuminuric toxemias of pregnancy. Clinics 4, 1011–1015 (1945).

  18. Robertson, W. B., Brosens, I. & Dixon, H. G. The pathological resonse of the vessels of the placental bed to hypertensive pregnancy. J. Pathol. Bacteriol. 93, 581–592 (1967).

  19. Labarrere, C. A. Acute atherosis. A histopathological hallmark of immune aggression? Placenta 9, 95–108 (1988).

  20. Staff , A. C., Dechend, R. & Redman, C. W. Review: Preeclampsia, acute atherosis of the spiral arteries and future cardiovascular disease: two new hypotheses. Placenta 34 (Suppl.), S73–S78 (2013).

  21. Young, J. The aetiology of eclampsia and albuminuria and their relation to accidental haemorrhage: (an anatomical and experimental investigation.). Proc. R. Soc. Med. 7, 307–348 (1914).

  22. Nelson DB, Ziadie MS, McIntire DD, et al: Placental pathology suggesting that preeclampsia is more than one disease. Am J Obstet Gynecol 210:66.e1, 2014.

  23. Brosens I, Pijnenborg R, Vercruysse L, et al: The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol 204(3):193, 2011.

  24. Staff AC, Sibai BM, Cunningham FG: Prevention of preeclampsia and eclampsia. In Taylor RN, Roberts JM, Cunningham FG (eds): Chesley’s Hypertensive Disorders in Pregnancy. Amsterdam, Academic Press, 2014.

  25. Tinnakorn Chaiworapongsa, Piya Chaemsaithong, Lami Yeo & Roberto Romero. Preeclampsia part 1: current understanding of its Pathophysiology. Nature Reviews Nephrology. 2014; 10, 466–480.

  26. Kublickiene K.R., Cockell A.P., Nisell H., Poston L. (1997) Role of nitric oxide in the regulation of vascular tone in pressurized and perfused resistance myometrial arteries from term pregnant women. Am J Obstet MGynecol 177:1263–1269.

  27. Cockell A.P., Poston L. (1997) Flowmediated vasodilatation is enhanced in normal pregnancy but reduced in preeclampsia. Hypertension 30:247–251.

  28. Kublickiene KR, Lindblom B, Kruger K, Nisell H. Preeclampsia: evidence for impaired shear stress-mediated NO release in uterine circulation. Am J Obstet Gynecol 2000; In press.

  29. Burton, G. J., Hempstock, J. & Jauniaux, E. Nutrition of the human fetus during the fi rst trimester—a review. Placenta 22 (Suppl. A), S70–S77 (2001).

  30. Genbacev, O., Joslin, R., Damsky, C. H., Polliotti, B. M. & Fisher, S. J. Hypoxia alters early gestation human cytotrophoblast diff erentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J. Clin. Invest. 97, 540–550 (1996).

  31. Reshef Tal. The Role of Hypoxia and Hypoxia-Inducible Factor-1Alpha in Preeclampsia Pathogenesis. Biology of Reproduction, December 1, 2012 vol. 87 no. 6 134.

  32. Caniggia I, Mostachfi H, Winter J, Gassmann M, Lye SJ, Kuliszewski M, Post M. Hypoxia-inducible factor-1 mediates the biological eff ects of oxygen on human trophoblast diff erentiation through TGFbeta(3). J Clin Invest 2000; 105(5):577 587.

  33. Caniggia I, Grisaru-Gravnosky S, Kuliszewsky M, Post M, Lye SJ. Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J Clin Invest 1999; 103(12):1641 1650.

  34. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I. Increased expression of sFlt-1 in in vivo and in vitro models human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006; 291(4):R1085 R1093.

  35. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002; 277(46):43799 43808.

  36. Yinon Y, Nevo O, Xu J, Many A, Rolfo A, Todros T, Post M, Caniggia I. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol 2008; 172(1):77 85.

  37. Tal R, Shaish A, Barshack I, Polak- Charcon S, Afek A, Volkov A, Feldman B, Avivi C, Harats D. Eff ects of hypoxiainducible factor-1alpha overexpression in pregnant mice: possible implications for preeclampsia and intrauterine growth restriction. Am J Pathol 2010; 177(6):2950 2962.

  38. Kanasaki, K. et al. Defi ciency in catechol-Omethyltransferase and 2-methoxyoestradiol is associated with preeclampsia. Nature 453, 1117–1121 (2008).

  39. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, Parry S, Augustin HG, Gattone VH, Folkman J, Strauss JF, Kalluri R. Defi ciency in catechol-O-methyltransferase and 2-methoxyestradiol is associated with preeclampsia. Nature 2008; 453(7198):1117 1121.

  40. Lee SB, Wong AP, Kanasaki K, Xu Y, Shenoy VK, McElrath TF, Whitesides GM, Kalluri R. Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifi cally under hypoxic conditions. Am J Pathol 2010; 176(2):710 720.

  41. Gant, N. F., Chand, S., Whalley, P. J. & MacDonald, P. C. The nature of pressor responsiveness to angiotensin II in human pregnancy. Obstet. Gynecol. 43, 854 (1974).

  42. Dechend, R., Luft, F. C. & Lindheimer, M. in Chesley’s Hypertensive Disorders in Pregnancy (eds Lindheimer, M. D., Roberts, J. M. & Cunningham, G. C.) 287–296 (Elsevier, 2009).

  43. Brown MA, Zammit VC, Mitar DA, Whitworth JA. Renin-aldosterone relationships in pregnancy-induced hypertension. Am J Hypertens 1992; 5(6 pt1):366 371.

  44. Blumenfeld JD, Laragh JH. Management of hypertensive crises: the scientifi c basis for treatment decisions. Am J Hypertens 2001; 14(11 pt 1):1154 1167.

  45. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973; 52(11):2682 2689.

  46. Xia Y, Wen H, Bobst S, Day MC, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig 2003; 10(2):82 93.

  47. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudanhausen JW, Haller H, et al. Patients with preeclampsiadevelop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103(7):945 952.

  48. Parrish, M. R. et al. The eff ect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am. J. Hypertens. 23, 911–916 (2010).

  49. Thway TM, Shlykov SG, Day MC, Sanborn BM, Gilstrap LC III, ., Xia Y, Kellems RE. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 2004; 110(12):1612M 1619.

  50. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibodies induce preeclampsia in pregnant mice. Nat Med 2008; 14(8):855 862.

  51. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 2010; 55(2):386 393.

  52. Zhou CC, Ahmad S, Mi T, Xia L, Abbasi S, Hewett PW, Sun C, Ahmed A, Kellems RE, Xia Y. Angiotensin II induces soluble fmslike tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res 2007; 100(1):88 95.

  53. Herse, F. & LaMarca, B. Angiotensin II type 1 receptor autoantibody (AT1-AA)- mediated pregnancy hypertension. Am. J. Reprod. Immunol. 69, 413–418 (2013).

  54. Novotny, S. R. et al. Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats. Am. J. Physiol. Regul. Integr Comp. Physiol. 302, R1197–

  55. (2012).

  56. Xia, Y. & Kellems, R. E. Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. Circ. Res. 113, 78–87 (2013).

  57. Li, J., LaMarca, B. & Reckelhoff , J. F. A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model.

  58. Am. J. Physiol. Heart Circ. Physiol. 303, H1–H8 (2012).

  59. Dhillion, P. et al. IL-17-mediated oxidative stress is an important stimulator of AT1-AA and hypertension during pregnancy. Am. J.

  60. Physiol. Regul. Integr Comp. Physiol. 303, R353–R358 (2012).

  61. Girardi, G., Yarilin, D., Thurman, J. M., Holers, V. M. & Salmon, J. E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 203, 2165–2175 (2006).

  62. Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, Sjogren KG, Hjalmarson A, Muller-Esterl W, Hoebeke J. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 2000; 18(7):945 953.

  63. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352(6):558 569.

  64. Langer B, Grima M, Coquard C, Bader AM, Schlaeder G, Imbs JL. Plasma active renin, angiotensin I, and angiotensin II

  65. during pregnancy and in preeclampsia. Obstet Gynecol 1998; 91(2):196 202.

  66. Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439–442

  67. (1996).

  68. Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal

  69. cancer. N. Engl. J. Med. 349, 427–434 (2003).

  70. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009; 43(3):490 501.

  71. Cross SN, Ratner E, Rutherford TJ, Schwartz PE, Norwitz ER. Bevacizumabmediated interference with VEGF signaling is suffi cient to induce a preeclampsia-like syndrome in nonpregnant women. Rev Obstet Gynecol 2012; 5(1):2 8.

  72. Maynard, S. E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649–658 (2003).

  73. Levine, R. J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672–683 (2004).

  74. Chaiworapongsa, T. et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am. J. Obstet. Gynecol. 190, 1541–1550 (2004).

  75. Maynard, S. E. et al. Gestational angiogenic biomarker patterns in high risk preeclampsia groups. Am. J. Obstet. Gynecol. 53, e1–e9 (2013).

  76. Wolf, M. et al. Circulating levels of the antiangiogenic marker sFLT-1 are increased in fi rst versus second pregnancies. Am. J. Obstet. Gynecol. 193, 16–22 (2005).

  77. Bdolah, Y. et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am. J. Obstet. Gynecol. 198, 428.e1–428.e6 (2008).

  78. Cohen, A. et al. Circulating levels of the antiangiogenic marker soluble FMS-like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes. Diabetes Care 30, 375–377 (2007).

  79. Levine, R. J. et al. Soluble endoglin and other circulating antiangiogenic factors in 1005 (2006).

  80. Chaiworapongsa, T. et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of preeclampsia. J. Matern. Fetal Neonatal Med. 17, 3–18 (2005).

  81. Widmer, M. et al. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet. Gynecol. 109, 168–180 (2007).

  82. Romero, R. et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J. Matern. Fetal Neonatal Med. 21, 9–23 (2008).

  83. Chaiworapongsa, T. et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am. J. Obstet. Gynecol. 190, 1541–1550 (2004).

  84. Sela, S. et al. A novel human-specifi c soluble vascular endothelial growth factor receptor 1: cell-type-specifi c splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ. Res. 102, 1566–1574 (2008).

  85. Gilbert, J. S., Babcock, S. A. & Granger, J. P. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50, 1142–1147 (2007).

  86. Makris, A. et al. Uteroplacental ischemiaresults in proteinuric hypertension and elevated sFLT-1. Kidney Int. 71, 977–984 (2007).

  87. Rajakumar, A. et al. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension 59, 256–26 (2012).

  88. Zhao, H., Wong, R. J., Kalish, F. S., Nayak, N. R. & Stevenson, D. K. Eff ect of heme oxygenase-1 defi ciency on placental development. Placenta 30, 861–868 (2009).

  89. Lockwood, C. J. et al. Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt- 1) expression in fi rst trimester decidua: implications for preeclampsia. Am. J. Pathol. 170, 1398–1405 (2007).

  90. Nagamatsu, T. et al. Cytotrophoblasts upregulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145, 4838– 4845 (2004).

  91. Kendall, R. L. & Thomas, K. A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl Acad. Sci. USA90, 10705–10709 (1993).

  92. Esser, S. et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J. Cell Biol. 140, 947–959 (1998).

  93. Maynard, S. E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649–658 (2003).

  94. Sandrim, V. C. et al. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension 52, 402–407 (2008).

  95. Cindrova-Davies, T., Sanders, D. A., Burton, G. J. & Charnock-Jones, D. S. Soluble FLT1 sensitizes endothelial cells to infl ammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovasc. Res. 89, 671–679 (2011).

  96. Eremina, V. et al. Glomerular-specifi c alterations of VEGF-A expression lead

  97. to distinct congenital and acquired renal

  98. diseases. J. Clin. Invest. 111, 707–716

  99. (2003).

  100. Craici, I. M. et al. Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study. Hypertension 61, 1289–1296 (2013).

  101. Chen, G. et al. Eff ects of angiogenic factors, antagonists, and podocyte injury on development of proteinuria in preeclampsia. Reprod. Sci. 20, 579–588 (2013).

  102. Spargo BH, McCartney C, Winemiller R. Glomerular capillary endotheliosis in toxemia of pregnancy. Arch Pathol. 1959; 13:593-599.

  103. Lafayette RA, Malik T, Druzin M, et al. The dynamics of glomerular fi ltration after caesarean section. J Am Soc Nephrol. 1999; 10:1561-1565.

  104. Govan AD. Renal changes in eclampsia. J Pathol Bacteriol. 1954;67:311-322.

  105. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, et al. 2011. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124: 940–950.

  106. Strevens H, et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG. 2003;110:831-836.

  107. Brownfoot FC, Hastie R, Hannan NJ, et al. Metformin as a prevention and treatment for preeclampsia: eff ects on soluble fmslike tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol 2016.

  108. Austgulen, R., Lien, E., Vince, G., and Redman, C.W. Increased maternal plasmalevels of soluble adhesion molecules (ICAM-1, VCAM-1, E-selectin) in preeclampsia. Eur J Obstet Gynecol Reprod Biol. 1997; 71: 53–58.

  109. Chaiworapongsa, T., Romero, R., Yoshimatsu, J. et al. Soluble adhesion molecule profi le in normal pregnancy and preeclampsia. J Matern Fetal Neonatal Med. 2002; 12: 19–27.

  110. Borzychowski, A.M., Sargent, I. L., and Redman, C.W. Infl ammation and preeclampsia. Semin Fetal Neonat Med. 2006; 11: 309–316.

Downloads

Pubblicato

2024-05-22

Come citare

Kaçulini, E., Koroshi, A., Idrizi, A., & Shehu, A. (2024). Preeklampsia – Nga fiziopatologjia tek mjekimi. Optime, (2), 82–100. https://doi.org/10.55312/op.vi2.4521

Fascicolo

N. 2 (2016): Optime

Sezione

Shkenca Mjekësore

Categorie